Serologic response to hepatitis B vaccine in children receiving multiple blood transfusions.
Three doses of the commercially available hepatitis B vaccine were administered to each of 43 anti-hepatitis B surface antigen antibody-negative children (including 32 hemophiliacs) who were regularly receiving blood product transfusions. Forty-two (98%) of them had demonstrable anti-hepatitis B surface antigen antibody in their serum, indicating that this group of patients responds favorably to the vaccine.
D000293:Adolescent; D000740:Anemia / Q000628:therapy; D001803:Blood Transfusion; D002648:Child; D002675:Child, Preschool; D006467:Hemophilia A / Q000628:therapy; D006509:Hepatitis B / Q000517:prevention & control*; D006510:Hepatitis B Antibodies / Q000096:biosynthesis*; D006515:Hepatitis B virus / Q000276:immunology; D006801:Humans; D007223:Infant; D014765:Viral Vaccines / Q000276:immunology*
D006510:Hepatitis B Antibodies; D014765:Viral Vaccines